Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  INC Research Holdings Inc    

INC RESEARCH HOLDINGS INC
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Glancy Prongay & Murray LLP : Continues Investigation on Behalf of INC Research Holdings, Inc. Investors (INCR)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 09:01pm CEST

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of INC Research Holdings, Inc. (“INCR” or the “Company”) (NASDAQ: INCR) investors concerning the Company and its officers’ possible violations of federal securities law. To obtain information or aid in the investigation, please visit the INCR page on our website at https://www.glancylaw.com/case/inc-research-holdings-inc.

On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. The price of INC Research stock fell significantly following the announcement.

On this news, INCR’s stock price fell nearly 30%, or $16.35 per share, to close at $41.15 per share on November 9, 2017, thereby injuring investors.

If you purchased INCR securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INC RESEARCH HOLDINGS INC
06/13SYNEOS HEALTH : to lay off 98 amid changing business needs
AQ
06/08SYNEOS HEALTH : Consulting Releases 10th Annual Biopharmaceutical Dealmakers Sur..
AQ
06/06SYNEOS HEALTH : Consulting Releases 10th Annual Biopharmaceutical Dealmakers Sur..
AQ
06/06SYNEOS HEALTH : to Present Actionable Commercial Insights Designed for Biopharma..
AQ
06/05SYNEOS HEALTH : Consulting Releases 10th Annual Biopharmaceutical Dealmakers Sur..
AQ
06/05Syneos Health to Present Actionable Commercial Insights Designed for Biopharm..
GL
05/25SYNEOS HEALTH, INC. : Change in Directors or Principal Officers, Submission of M..
AQ
05/21Syneos Health to Present at Upcoming Investors Conferences
GL
05/15SYNEOS HEALTH : Promotes Jason Meggs to Chief Financial Officer
AQ
05/10INC. (NASDAQ : INCR) Files An 8-K Other Events
AQ
More news
News from SeekingAlpha
01/03INC Research CFO exiting post at April's end 
2017INC Research Holdings 2017 Q3 - Results - Earnings Call Slides 
2017INC Research's (INCR) CEO Alistair MacDonald on Q3 2017 Results - Earnings Ca.. 
2017Midday Gainers / Losers 
2017INC Research misses by $0.08, misses on revenue 
Financials ($)
Sales 2018 4 464 M
EBIT 2018 448 M
Net income 2018 26,0 M
Debt 2018 2 509 M
Yield 2018 -
P/E ratio 2018 196,88
P/E ratio 2019 34,50
EV / Sales 2018 1,66x
EV / Sales 2019 1,49x
Capitalization 4 887 M
Chart INC RESEARCH HOLDINGS INC
Duration : Period :
INC Research Holdings Inc Technical Analysis Chart | US45329R1095 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 50,8 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Alistair Macdonald Chief Executive Officer & Director
Michael A. Bell Chairman
Jason M. Meggs Chief Financial Officer & Executive Vice President
Kenneth F. Meyers Independent Director
Linda S. Harty Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INC RESEARCH HOLDINGS INC-5.39%4 887
CELLTRION, INC.--.--%34 574
IQVIA HOLDINGS INC8.22%21 638
LONZA GROUP1.10%20 183
INCYTE CORPORATION-23.96%15 266
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 678